XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.3
STATEMENTS OF CASH FLOWS - USD ($)
6 Months Ended
Aug. 31, 2025
Aug. 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (665,318) $ (741,170)
Adjustments to reconcile net loss to net cash used by operating activities:    
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D. 493,250 471,125
Changes in operating assets and liabilities    
Prepaids (400) 600
Accounts payable 6,926 68,293
Accrued liabilities 21,492 (6,476)
NET CASH USED BY OPERATING ACTIVITIES (144,050) (207,628)
CASH FLOWS FROM FINANCING ACTIVITIES    
Contribution of capital 144,134 207,534
NET CASH PROVIDED BY FINANCING ACTIVITIES 144,134 207,534
NET INCREASE (DECREASE) IN CASH 84 (94)
CASH AT BEGINNING OF PERIOD 847 1,310
CASH AT END OF PERIOD $ 931 $ 1,216